643094-10-4

Upstream product

• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 108-95-2 phenol 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 

Downstream Products

• 364353-92-4 2-phenoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)benzonitrile 
• 364354-24-5 2-phenoxy-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzaldehyde 
• 1307882-84-3 3-phenoxybiphenyl-4,4'-dicarbaldehyde 
• 1446819-53-9 tert-butyl 4-[(4-bromo-2-phenoxyphenyl)methyl]piperazine-1-carboxylate 
• 1446819-54-0 tert-butyl 4-[[4-(3-methylphenyl)-2-phenoxyphenyl]methyl]piperazine-1-carboxylate 
• 1446819-55-1 1-[[4-(3-methylphenyl)-2-phenoxyphenyl]methyl]piperazine 
• 1446818-30-9 1,1,1,3,3,3-hexafluoropropan-2-yl 4-[[4-(3-methylphenyl)-2-phenoxyphenyl]methyl]piperazine-1-carboxylate 
• 38732-11-5 3-phenyl-9H-xanthene 
• 500286-36-2 3-bromo-9H-xanthene-9-one 

Relevant academic research and scientific papers

CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME

This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compunds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.

CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME

Provided herein are carbamate compounds which may be useful in the treatment of, for example, pain, solid tumors and/or obesity.

Synthesis of tri-substituted biaryl based trianglimines: Formation of C3-symmetrical and non-symmetrical regioisomers

2-Functionalised aromatic monoaldehydes were synthesised in good to excellent yields by reacting 4-bromo-2-fluorobenzaldehyde with different secondary amines and phenol. The Suzuki-coupling reaction of the newly functionalised aromatic monoaldehydes with

Pyrrolopyrimidines as therapeutic agents

Chemical compounds having structural formula I and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatiod arthritis, disorders of the immune system, trasplant refections and imflammatory disorders.